Partial
Mostly Aligned
Patient Risk:
Low
Summary
Indication-related claims (edema, hypertension, heart failure, kidney disease) are supported by labeling. Claims about generic injections, pricing, and insurance coverage are not addressed in the FDA label. Overall partial alignment.
Category Scores
Accurate Statements
Lasix is a brand name for furosemide.
Label uses LASIX and identifies it as furosemide.
Furosemide is a loop diuretic.
Pharmacology describes furosemide as a loop diuretic.
Furosemide is used to treat fluid retention (edema).
Edema indication documented in the label.
Furosemide is used to treat high blood pressure.
Hypertension indication documented in the label.
Furosemide is used to treat heart failure.
Heart failure-related edema described under edema indications.
Furosemide is used to treat kidney disease.
Kidney disease-related edema described under edema indications.
Unsupported Statements
Generic furosemide injections are widely available.
Label does not provide information on generic formulation availability.
Generic furosemide injections are typically more affordable than the brand-name Lasix.
Pricing/affordability is not addressed in FDA labeling.
Insurance coverage for injection Lasix varies by plan.
Insurance coverage information is not included in FDA labeling.
Many insurance providers cover furosemide, including its injectable form.
Insurance coverage specifics are not provided in labeling.
Contradictions
Important Omissions
No dosage or administration details for injections are addressed by the claims; label contains pharmacology and indications but not dosage statements within the evaluated claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation focused on alignment with label; no safety or dosing inconsistencies were identified within the claims that are on-label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Restrict claims to those supported by the label (edema, hypertension, heart failure-related edema, and kidney-disease-related edema). Exclude statements about generic availability, pricing, and insurance coverage, which are not addressed in labeling. When evaluating, map statements to explicit label sections (Edema, Hypertension, CLINICAL PHARMACOLOGY) to improve traceability.